{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T06:43:35Z","timestamp":1649141015464},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Rostock"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00066-020-01600-4","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T14:04:22Z","timestamp":1584108262000},"page":"488-491","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Positronenemissionstomographie gest\u00fctzte Behandlung des Morbus Hodgkin im fr\u00fchen g\u00fcnstigen Stadium: Endergebnisse der Deutschen Hodgkin Studiengruppe (DHSG)"],"prefix":"10.1007","volume":"196","author":[{"given":"Bernd","family":"Frerker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"key":"1600_CR1","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.19.00964","volume":"37","author":"M Fuchs","year":"2019","unstructured":"Fuchs\u00a0M, Goergen\u00a0H, Kobe\u00a0C, Kuhnert\u00a0G, Lohri\u00a0A et al (2019) HD16 \u2013 positron emission tomography-guided treatment in early-stage favorable Hodgkin Lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group. HD16 trial. J\u00a0Clin Oncol 37:2835\u20132845. https:\/\/doi.org\/10.1200\/JCO.19.00964","journal-title":"J Clin Oncol"},{"key":"1600_CR2","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1200\/JCO.2001.19.11.2905","volume":"19","author":"E D\u00fchmke","year":"2001","unstructured":"D\u00fchmke\u00a0E, Franklin\u00a0J, Pfreundschuh\u00a0M, Sehlen\u00a0S, Willich\u00a0N et al (2001) HD04 \u2013 Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin\u2019s disease: long-term results of a\u00a0randomized trial of radiotherapy alone. HD04 trial. J\u00a0Clin Oncol 19:2905\u20132914. https:\/\/doi.org\/10.1200\/JCO.2001.19.11.2905","journal-title":"J Clin Oncol"},{"key":"1600_CR3","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","volume":"25","author":"A Engert","year":"2007","unstructured":"Engert\u00a0A, Franklin\u00a0J, Eich\u00a0HT, Brillant\u00a0C, Sehlen\u00a0S et al (2007) HD07 \u2013 Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin\u2019s lymphoma: final results of the GHSG HD7 trial. HD07 trial. J\u00a0Clin Oncol 25:3495\u20133502. https:\/\/doi.org\/10.1200\/JCO.2006.07.0482","journal-title":"J Clin Oncol"},{"key":"1600_CR4","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert\u00a0A, Pl\u00fctschow\u00a0A, Eich\u00a0HT, Lohri\u00a0A, D\u00f6rken\u00a0B et al (2010) HD10 \u2013 Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma. HD10 tri. N\u00a0Engl J Med 363:640\u2013652. https:\/\/doi.org\/10.1056\/NEJMoa1000067","journal-title":"N Engl J Med"},{"key":"1600_CR5","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1200\/JCO.1998.16.3.830","volume":"16","author":"L Specht","year":"1998","unstructured":"Specht\u00a0L, Gray\u00a0RG, Clarke\u00a0MJ, Peto\u00a0R (1998) Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin\u2019s disease: a\u00a0meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin\u2019s Disease Collaborative Group. J\u00a0Clin Oncol 16:830\u2013843. https:\/\/doi.org\/10.1200\/JCO.1998.16.3.830","journal-title":"J Clin Oncol"},{"key":"1600_CR6","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"A Engert","year":"2003","unstructured":"Engert\u00a0A, Schiller\u00a0P, Josting\u00a0A, Herrmann\u00a0R, Koch\u00a0P et al (2003) HD08 \u2013 Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin\u2019s lymphoma: results of the HD8 trial of the German Hodgkin\u2019s Lymphoma Study Group. HD08-trial. J\u00a0Clin Oncol 21:3601\u20133608. https:\/\/doi.org\/10.1200\/JCO.2003.03.023","journal-title":"J Clin Oncol"},{"key":"1600_CR7","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","volume":"24","author":"EM Noordijk","year":"2006","unstructured":"Noordijk\u00a0EM, Carde\u00a0P, Dupouy\u00a0N, Hagenbeek\u00a0A, Krol\u00a0ADG et al (2006) H7F \u2013 Combined-modality therapy for clinical stage I or II Hodgkin\u2019s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. H7F-trial. J\u00a0Clin Oncol 24:3128\u20133135. https:\/\/doi.org\/10.1200\/JCO.2005.05.2746","journal-title":"J Clin Oncol"},{"key":"1600_CR8","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","volume":"385","author":"K Behringer","year":"2015","unstructured":"Behringer\u00a0K, Goergen\u00a0H, Hitz\u00a0F, Zijlstra\u00a0JM, Greil\u00a0R et al (2015) HD13 \u2013 Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. HD13 trial. Lancet 385:1418\u20131427. https:\/\/doi.org\/10.1016\/S0140-6736(14)61469-0","journal-title":"Lancet"},{"key":"1600_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","volume":"107","author":"M Hutchings","year":"2006","unstructured":"Hutchings\u00a0M, Loft\u00a0A, Hansen\u00a0M, Pedersen\u00a0LM, Buhl\u00a0T et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52\u201359. https:\/\/doi.org\/10.1182\/blood-2005-06-2252","journal-title":"Blood"},{"key":"1600_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3109\/10428194.2014.919635","volume":"56","author":"E Bednaruk-M\u0142y\u0144ski","year":"2015","unstructured":"Bednaruk-M\u0142y\u0144ski\u00a0E, Pie\u0144kowska\u00a0J, Sk\u00f3rzak\u00a0A, Ma\u0142kowski\u00a0B, Kulikowski\u00a0W et al (2015) Comparison of positron emission tomography\/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma. Leuk Lymphoma 56:377\u2013382. https:\/\/doi.org\/10.3109\/10428194.2014.919635","journal-title":"Leuk Lymphoma"},{"key":"1600_CR11","unstructured":"Leitlinienprogramm Onkologie (2019) S3-Leitlinie \u2013 Diagnostik, Therapie und Nachsorge des Hodgkin Lymphoms bei erwachsenen Patienten. Empfehlung 3.14: PET zum Staging, S.44. Version 2.1. AWMF-Registernummer: 018\/029 2019. https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Hodgkin\/Version_2\/LL_Hodgkin-Lymphom_Langversion_2.1.pdf. Zugegriffen: 24.12.2019"},{"key":"1600_CR12","first-page":"475","volume":"91","author":"A Gallamini","year":"2006","unstructured":"Gallamini\u00a0A, Rigacci\u00a0L, Merli\u00a0F, Nassi\u00a0L, Bosi\u00a0A et\u00a0al (2006) The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin\u2019s disease. Haematologica 91:475\u2013481","journal-title":"Haematologica"},{"key":"1600_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ajh.23994","volume":"90","author":"L Rigacci","year":"2015","unstructured":"Rigacci\u00a0L, Puccini\u00a0B, Zinzani\u00a0PL, Biggi\u00a0A, Castagnoli\u00a0A et al (2015) The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: a multicentric study by the fondazione italiana linfomi (FIL). Am J Hematol 90:499\u2013503. https:\/\/doi.org\/10.1002\/ajh.23994","journal-title":"Am J Hematol"},{"key":"1600_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1046\/j.1365-2141.2001.03169.x","volume":"115","author":"K Spaepen","year":"2001","unstructured":"Spaepen\u00a0K, Stroobants\u00a0S, Dupont\u00a0P, Thomas\u00a0J, Vandenberghe\u00a0P et al (2001) Can positron emission tomography with (18)F-fluorodeoxyglucose after first-line treatment distinguish Hodgkin\u2019s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 115:272\u2013278. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.03169.x","journal-title":"Br J Haematol"},{"key":"1600_CR15","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5.","volume":"379","author":"A Engert","year":"2012","unstructured":"Engert\u00a0A, Haverkamp\u00a0H, Kobe\u00a0C, Markova\u00a0J, Renner\u00a0C et al (2012) HD15 \u2013 Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a\u00a0randomised, open-label, phase 3 non-inferiority trial. HD15-trial. Lancet 379:1791\u20131799. https:\/\/doi.org\/10.1016\/S0140-6736(11)61940-5","journal-title":"Lancet"},{"key":"1600_CR16","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2018","unstructured":"Borchmann\u00a0P, Goergen\u00a0H, Kobe\u00a0C, Lohri\u00a0A, Greil\u00a0R et al (2018) HD18 \u2013 PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. HD18-trial. Lancet 390:2790\u20132802. https:\/\/doi.org\/10.1016\/S0140-6736(17)32134-7","journal-title":"Lancet"},{"key":"1600_CR17","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford\u00a0J, Illidge\u00a0T, Counsell\u00a0N, Hancock\u00a0B, Pettengell\u00a0R et al (2015) RAPID \u2013 results of a\u00a0trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. RADIP-trial. N\u00a0Engl J Med 372:1598\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1408648","journal-title":"N Engl J Med"},{"key":"1600_CR18","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9\u00a0MPE, Girinsky\u00a0T, Federico\u00a0M, Reman\u00a0O, Fortpied\u00a0C et al (2017) H10 \u2013 early positron emission tomography response-adapted treatment in stage I and II hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. H10-trial. J\u00a0Clin Oncol 35:1786\u20131794. https:\/\/doi.org\/10.1200\/JCO.2016.68.6394","journal-title":"J Clin Oncol"},{"key":"1600_CR19","unstructured":"Leitlinienprogramm Onkologie (2019) S3-Leitlinie \u2013 Diagnostik, Therapie und Nachsorge des Hodgkin Lymphoms bei erwachsenen Patienten. Empfehlung 5.6:\u00a0PET nach 2 Zyklen ABVD im fr\u00fchen Stadium, S. 52\u202ff. Version 2.1. AWMF-Registernummer: 018\/029. https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Hodgkin\/Version_2\/LL_Hodgkin-Lymphom_Langversion_2.1.pdf. Zugegriffen: 24.12.2019"},{"key":"1600_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1200\/JCO.2004.01.021","volume":"22","author":"S Laskar","year":"2004","unstructured":"Laskar\u00a0S, Gupta\u00a0T, Vimal\u00a0S, Muckaden\u00a0MA, Saikia\u00a0TK et\u00a0al (2004) Consolidation radiation after complete remission in Hodgkin\u2019s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a\u00a0need? J\u00a0Clin Oncol 22:62\u201368. https:\/\/doi.org\/10.1200\/JCO.2004.01.021","journal-title":"J Clin Oncol"},{"key":"1600_CR21","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1200\/JCO.2002.12.007","volume":"20","author":"JB Nachman","year":"2002","unstructured":"Nachman\u00a0JB, Sposto\u00a0R, Herzog\u00a0P, Gilchrist\u00a0GS, Wolden\u00a0SL et al (2002) Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin\u2019s disease who achieve a\u00a0complete response to chemotherapy. J\u00a0Clin Oncol 20:3765\u20133771. https:\/\/doi.org\/10.1200\/JCO.2002.12.007","journal-title":"J Clin Oncol"},{"key":"1600_CR22","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1200\/JCO.2005.01.911","volume":"23","author":"GP Canellos","year":"2005","unstructured":"Canellos\u00a0GP (2005) Chemotherapy alone for early Hodgkin\u2019s lymphoma: an emerging option. J\u00a0Clin Oncol 23:4574\u20134576. https:\/\/doi.org\/10.1200\/JCO.2005.01.911","journal-title":"J Clin Oncol"},{"key":"1600_CR23","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","volume":"89","author":"L Specht","year":"2014","unstructured":"Specht\u00a0L, Yahalom\u00a0J, Illidge\u00a0T, Berthelsen\u00a0AK, Constine\u00a0LS et\u00a0al (2014) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 89:854\u2013862. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.05.005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1600_CR24","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.clon.2015.03.005","volume":"27","author":"L Murray","year":"2015","unstructured":"Murray\u00a0L, Sethugavalar\u00a0B, Robertshaw\u00a0H, Bayman\u00a0E, Thomas\u00a0E et\u00a0al (2015) Involved node, site, field and residual volume radiotherapy for Lymphoma: a comparison of organ at risk dosimetry and second malignancy risks. Clin Oncol 27:401\u2013410. https:\/\/doi.org\/10.1016\/j.clon.2015.03.005","journal-title":"Clin Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01600-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-020-01600-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01600-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:07:32Z","timestamp":1615594052000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-020-01600-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1600"],"URL":"https:\/\/doi.org\/10.1007\/s00066-020-01600-4","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,13]]},"assertion":[{"value":"13 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.\u00a0Frerker und G.\u00a0Hildebrandt geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}